Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas.

To identify, in high-resolution regions of DNA, the copy number changes associated with outcome in patients with diffuse large B-cell lymphoma (DLBCL), a disease with an approximately 50% mortality rate, we performed array comparative genomic hybridization (array-CGH) on specimens from 64 patients with newly diagnosed DLBCL treated with anthracycline-based chemotherapy. For the entire cohort, 55 commonly gained/lost regions, ranging in size from less than 1 Mbp to entire chromosomes, were identified using 1- to 2-Mbp and 2- to 4-Mbp resolution BAC arrays. Copy number changes of 9 minimal regions significantly correlated with overall survival, of which 6 were 10 Mbp or smaller. On multivariate analysis, loss of chromosomes 2 (2.4-4.1 Mbp) and 16 (33.8-35.6 Mbp) were found to be prognostic indicators of poor survival, independent of clinical features routinely used to predict outcome. Loss of chromosome 1 (78.2-79.1 Mbp) was predictive of good outcome. For a subset of 55 specimens classified according to cell-of-origin expression signature subtype, gain of chromosome 12 (45.4-53.8 Mbp) was found to be significantly associated with the germinal center B-cell-like DLBCL subtype. Overall, array-CGH identified relatively small genomic regions associated with outcome, which, along with follow-up expression studies, may reveal target genes important in DLBCL clinical behavior.

[1]  H. Tagawa,et al.  Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma , 2004, Oncogene.

[2]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[3]  A. López-Guillermo,et al.  Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Offit,et al.  REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. , 1996, Blood.

[5]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[6]  S. Lowe,et al.  A microRNA polycistron as a potential human oncogene , 2005, Nature.

[7]  J. Cigudosa,et al.  Chromosomal and gene amplification in diffuse large B-cell lymphoma. , 1998, Blood.

[8]  L. Pasqualucci,et al.  Expression of the AID protein in normal and neoplastic B cells. , 2004, Blood.

[9]  D. Weisenburger,et al.  Similar patterns of genomic alterations characterize primary mediastinal large‐B‐cell lymphoma and diffuse large‐B‐cell lymphoma , 2002, Genes, chromosomes & cancer.

[10]  A. Zelenetz,et al.  Molecular cytogenetic analysis of genomic instability at the 1q12–22 chromosomal site in B‐cell non‐Hodgkin lymphoma , 2002, Genes, chromosomes & cancer.

[11]  A. Stoffel,et al.  The p73 locus is commonly deleted in non-Hodgkin's lymphomas. , 2004, Leukemia research.

[12]  J. Teruya-Feldstein,et al.  Recurring chromosomal abnormalities in non-Hodgkin's lymphoma: biologic and clinical significance. , 2000, Seminars in hematology.

[13]  H. Tagawa,et al.  Genome-Wide Array-Based Comparative Genomic Hybridization of Diffuse Large B-Cell Lymphoma , 2004, Cancer Research.

[14]  J. Inazawa,et al.  GPC5 is a possible target for the 13q31-q32 amplification detected in lymphoma cell lines , 2003, Journal of Human Genetics.

[15]  S. Okamura,et al.  Isolation and characterization of a novel TP53‐inducible gene, TP53TG3 , 1999, Genes, chromosomes & cancer.

[16]  L. Feuk,et al.  Detection of large-scale variation in the human genome , 2004, Nature Genetics.

[17]  M. Minden,et al.  Molecular cytogenetic characterization of non‐Hodgkin lymphoma cell lines , 2002, Genes, chromosomes & cancer.

[18]  J. Teruya-Feldstein,et al.  Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. , 2002, Human pathology.

[19]  H. Tagawa,et al.  Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. , 2005, Blood.

[20]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[21]  H. Döhner,et al.  Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract. , 1998, Blood.

[22]  D G Oscier,et al.  The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. , 2001, Blood.

[23]  C. Perou,et al.  Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer , 2004, Cancer Research.

[24]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[25]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[26]  D. Cox.  Regression Models and Life-Tables , 1972 .

[27]  Hiroyuki Tagawa,et al.  Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. , 2004, Cancer research.

[28]  Ash A. Alizadeh,et al.  The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. , 2002, Blood.

[29]  D. Weisenburger,et al.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[31]  H. Kohlhammer,et al.  Hidden gene amplifications in aggressive B-cell non-Hodgkin lymphomas detected by microarray-based comparative genomic hybridization , 2003, Oncogene.

[32]  Adrian Wiestner,et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Golub,et al.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. , 2004, Blood.

[34]  Nallasivam Palanisamy,et al.  Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. , 2004, Blood.

[35]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[36]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.